ATE533770T1 - Pyrazolopyrimidine als proteinkinaseinhibitoren - Google Patents

Pyrazolopyrimidine als proteinkinaseinhibitoren

Info

Publication number
ATE533770T1
ATE533770T1 AT06816408T AT06816408T ATE533770T1 AT E533770 T1 ATE533770 T1 AT E533770T1 AT 06816408 T AT06816408 T AT 06816408T AT 06816408 T AT06816408 T AT 06816408T AT E533770 T1 ATE533770 T1 AT E533770T1
Authority
AT
Austria
Prior art keywords
pyrazolopyrimidines
protein kinase
kinase inhibitors
inhibitors
protein
Prior art date
Application number
AT06816408T
Other languages
English (en)
Inventor
Kamil Paruch
Timothy Guzi
Michael Dwyer
Carmen Alvarez
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE533770T1 publication Critical patent/ATE533770T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06816408T 2005-10-06 2006-10-04 Pyrazolopyrimidine als proteinkinaseinhibitoren ATE533770T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72419705P 2005-10-06 2005-10-06
PCT/US2006/039136 WO2007041712A1 (en) 2005-10-06 2006-10-04 Pyrazolopyrimidines as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE533770T1 true ATE533770T1 (de) 2011-12-15

Family

ID=37560916

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06816408T ATE533770T1 (de) 2005-10-06 2006-10-04 Pyrazolopyrimidine als proteinkinaseinhibitoren

Country Status (18)

Country Link
US (1) US7776865B2 (de)
EP (1) EP1931676B1 (de)
JP (2) JP5052518B2 (de)
KR (1) KR20080063806A (de)
CN (1) CN101321760A (de)
AR (1) AR056206A1 (de)
AT (1) ATE533770T1 (de)
AU (1) AU2006299338A1 (de)
BR (1) BRPI0617150A2 (de)
CA (1) CA2624882C (de)
EC (1) ECSP088350A (de)
IL (1) IL190598A0 (de)
NO (1) NO20082092L (de)
PE (1) PE20070543A1 (de)
RU (1) RU2008117298A (de)
TW (1) TW200745123A (de)
WO (1) WO2007041712A1 (de)
ZA (1) ZA200802995B (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008117298A (ru) * 2005-10-06 2009-11-20 Шеринг Корпорейшн (US) Пиразолопиримидины как ингибиторы протеинкиназ
JP5152922B2 (ja) * 2005-10-06 2013-02-27 メルク・シャープ・アンド・ドーム・コーポレーション プロテインキナーゼを阻害するためのピラゾロ［１，５−ａ］ピリミジン誘導体の使用およびプロテインキナーゼを阻害する方法
MX2008011430A (es) * 2006-03-08 2008-09-18 Novartis Ag Uso de derivados de pirazolo-[1,5a]-pirimidin-7-il-amina en el tratamiento de trastornos neurologicos.
US20070275963A1 (en) * 2006-05-22 2007-11-29 Schering Corporation PYRAZOLO[1,5-a]PYRIMIDINES
CA2668286C (en) 2006-11-03 2014-09-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
BRPI0718029A2 (pt) * 2006-11-06 2013-11-26 Supergen Inc Derivados de imidazo(1,2-b)piridazina e pirazolo(1,5-a)pirimidina e seu uso como inibidores da proteína cinase
JP2010526809A (ja) 2007-05-08 2010-08-05 シェーリング コーポレイション テモゾロミドを含む静脈内処方物を用いる治療方法
CA2685351A1 (en) * 2007-05-09 2008-11-20 Abbott Laboratories Inhibitors of protein kinases
WO2008141140A1 (en) * 2007-05-09 2008-11-20 Abbott Laboratories Condensed heterocyclic compounds as inhibitors of protein kinases
US8124759B2 (en) 2007-05-09 2012-02-28 Abbott Laboratories Inhibitors of protein kinases
EP2170886A1 (de) * 2007-07-02 2010-04-07 Cancer Research Technology Limited 9H-PYRIMIDO[4,5-B]INDOLE, 9H-PYRIDO[4ý,3ý:4,5]PYRROLO[2,3-D]PYRIDINE UND 9H-1,3,6,9-TETRAAZAFLUORENE ALS INHIBITOREN DER FUNKTION VON CHK1-KINASE
PE20091195A1 (es) * 2007-11-07 2009-08-06 Schering Corp Nuevos moduladores de los puntos de control del ciclo celular y su uso en combinacion con inhibidores de quinasa de punto de control
CN101952283B (zh) * 2007-12-14 2013-04-17 霍夫曼-拉罗奇有限公司 咪唑并[1，2-a]吡啶和咪唑并[1，2-b]哒嗪衍生物
US8426441B2 (en) * 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
EP2265603B1 (de) * 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitoren des bmp-signalpfades
AU2009257926A1 (en) * 2008-05-12 2009-12-17 Amnestix, Inc. Compounds for Rho kinase inhibition and for improving learning and memory
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
PA8851101A1 (es) * 2008-12-16 2010-07-27 Lilly Co Eli Compuesto amino pirazol
EP2396330B1 (de) * 2009-02-13 2016-04-06 Bayer Intellectual Property GmbH Kondensierte pyrimidine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
UA110324C2 (en) * 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
WO2011028638A1 (en) 2009-09-04 2011-03-10 Schering Corporation Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
CN108774237A (zh) * 2009-12-01 2018-11-09 Abbvie 公司 新的三环化合物
CN103189379A (zh) * 2010-07-13 2013-07-03 拜耳知识产权有限责任公司 双环嘧啶
JP5926727B2 (ja) * 2010-07-28 2016-05-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾ［１，２−ｂ］ピリダジン
EP2723746A1 (de) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Als art-kinasehemmer nützliche verbindungen
US9416132B2 (en) 2011-07-21 2016-08-16 Tolero Pharmaceuticals, Inc. Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
RU2641693C2 (ru) 2011-11-09 2018-01-22 Кансер Ресёрч Текнолоджи Лимитед Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение
CA2860724A1 (en) * 2012-01-10 2013-07-18 Bayer Intellectual Property Gmbh Substituted pyrazolopyrimidines as akt kinase inhibitors
EP3210980B1 (de) 2012-05-15 2024-04-03 Cancer Research Technology Ltd Verfahren zur herstellung von 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluormethyl)-2-pyridyl]amino]pyrazin-2-carbonitril
CN107501275B (zh) 2012-12-07 2019-11-22 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
ME03780B (de) 2013-01-15 2021-04-20 Incyte Holdings Corp Thiazolcarboxamid-derivate und pyridincarboxamid-derivate verwendbar als pim kinase inhibitoren
EP2970311A4 (de) 2013-03-14 2016-11-23 Brigham & Womens Hospital Bmp-hemmer und verfahren zur verwendung davon
EP2970286A1 (de) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Kondensierte pyrazolopyrimidinderivate als inhibitoren der atr-kinase
EP2970289A1 (de) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Als atr-kinaseinhibitoren nützliche verbindungen
WO2014143242A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2015008844A1 (ja) 2013-07-18 2015-01-22 大鵬薬品工業株式会社 Ｆｇｆｒ阻害剤耐性癌の治療薬
JP6084291B2 (ja) 2013-07-18 2017-02-22 大鵬薬品工業株式会社 Ｆｇｆｒ阻害剤の間歇投与用抗腫瘍剤
CN105658653A (zh) 2013-08-23 2016-06-08 因赛特公司 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
RU2720408C2 (ru) 2013-12-06 2020-04-29 Вертекс Фармасьютикалз Инкорпорейтед Способ получения ингибиторов atr киназы (варианты)
AU2015271030B2 (en) 2014-06-05 2019-05-16 Vertex Pharmaceuticals Incorporated Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo [1,5-a] pyrimidin-3-carboxamide compound useful as ATR kinase inhibitor, the preparation of said compound and different solid forms thereof
ES2733847T3 (es) 2014-06-17 2019-12-03 Vertex Pharma Método para tratar cáncer usando una combinación de inhibidores de CHK1 y ATR
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US10513521B2 (en) 2014-07-15 2019-12-24 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting BMP
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
CA2980888C (en) 2015-03-31 2018-03-06 Taiho Pharmaceutical Co., Ltd. Crystal of 3,5-disubstituted benzene alkynyl compound
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059357A1 (en) 2015-09-30 2017-04-06 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna damaging agents and atr inhibitors
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
TWI782906B (zh) 2016-03-04 2022-11-11 日商大鵬藥品工業股份有限公司 惡性腫瘤治療用製劑及組合物
BR112019024322A2 (pt) * 2017-05-22 2020-06-16 F. Hoffmann-La Roche Ag Compostos e composições terapêuticos e métodos de uso dos mesmos
CN117946114A (zh) 2017-07-28 2024-04-30 武田药品工业株式会社 Tyk2抑制剂与其用途
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
WO2019181876A1 (ja) 2018-03-19 2019-09-26 大鵬薬品工業株式会社 アルキル硫酸ナトリウムを含む医薬組成物
CN112236139A (zh) 2018-04-13 2021-01-15 大日本住友制药肿瘤公司 用于治疗骨髓增殖性肿瘤和与癌症相关的纤维化的pim激酶抑制剂
CN108586341B (zh) * 2018-05-25 2020-05-08 天津商业大学 酰胺类化合物和其药用盐及其制备方法和药物用途
EP3866789A4 (de) * 2018-10-15 2022-07-06 Nimbus Lakshmi, Inc. Tyk2-inhibitoren und verwendungen davon
CN109293630A (zh) * 2018-11-15 2019-02-01 山东大学 含取代吡唑类化合物及其制备方法与应用
WO2020167990A1 (en) 2019-02-12 2020-08-20 Tolero Pharmaceuticals, Inc. Formulations comprising heterocyclic protein kinase inhibitors
CN112457306A (zh) * 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
CN114957261B (zh) * 2022-05-17 2023-06-23 重庆文理学院 一种具有抗头颈癌作用的化合物及其制备方法和应用
WO2024097653A1 (en) 2022-10-31 2024-05-10 Sumitomo Pharma America, Inc. Pim1 inhibitor for treating myeloproliferative neoplasms

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3130633A1 (de) * 1981-08-01 1983-02-17 Basf Ag, 6700 Ludwigshafen 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide
DE69130683T2 (de) 1991-04-22 1999-05-06 Otsuka Pharma Co Ltd PYRAZOLO[1,5-a]PYRIMIDINDERIVATE UND SIE ENTHALTENDE ANTIINFLAMMATORISCHE MITTEL
EP0628559B1 (de) 1993-06-10 2002-04-03 Beiersdorf-Lilly GmbH Pyrimidinverbindungen und ihre Verwendung als Pharmazeutika
US5571813A (en) 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
KR100315837B1 (ko) 1994-06-21 2002-02-28 고리 히데아끼 피라졸로[1,5-a]피리미딘유도체
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
CA2291709A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
CA2314355A1 (en) 1997-12-13 1999-06-24 Bristol-Myers Squibb Company Use of pyrazolo ¢3,4-b! pyridine as cyclin dependent kinase inhibitors
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
EP1140938B1 (de) 1999-01-11 2003-08-27 Princeton University Kinase-inhibitoren mit hoher affinität zur ziel detektion und ihre verwendung
FR2805160B1 (fr) * 2000-02-23 2002-04-05 Oreal Compositions pour la teinture d'oxydation des fibres keratiniques comprenant un n(2-hydroxybenzene)-carbramate ou un n-(2-hydroxybenzene)-uree et une pyrazolopyrimidine, et procedes de teinture
YU4903A (sh) 2000-07-26 2006-03-03 Bristol-Myers Squibb Company N-/5-///5-alkil-2-oksazolil/metil/tio/-2-tiazolil/ karboksamidni inhibitori ciklin zavisnih kinaza
US6495582B1 (en) 2000-09-15 2002-12-17 Vertex Pharmaceuticals Incorporated Isoxazole compositions useful as inhibitors of ERK
US7067520B2 (en) 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
JP2002212076A (ja) * 2000-11-17 2002-07-31 Ishihara Sangyo Kaisha Ltd 縮合複素環化合物またはその塩を含有する糖尿病の予防または治療薬
WO2002050079A1 (fr) 2000-12-20 2002-06-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3)
CA2483306A1 (en) 2002-04-23 2003-11-06 Shionogi & Co., Ltd. Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
DE10223917A1 (de) 2002-05-29 2003-12-11 Bayer Cropscience Ag Pyrazolopyrimidine
AU2003240488A1 (en) 2002-06-04 2003-12-19 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
KR101088922B1 (ko) * 2002-09-04 2011-12-01 파마코페이아, 엘엘씨. 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘
JP2006522750A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法
PE20051089A1 (es) * 2004-01-22 2006-01-25 Novartis Ag Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina
JP5094412B2 (ja) * 2005-01-19 2012-12-12 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病治療用又は予防用のジペプチジルペプチダーゼ−ｉｖ阻害剤としての二環系ピリミジン
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
RU2008117298A (ru) * 2005-10-06 2009-11-20 Шеринг Корпорейшн (US) Пиразолопиримидины как ингибиторы протеинкиназ

Also Published As

Publication number Publication date
CA2624882A1 (en) 2007-04-12
CN101321760A (zh) 2008-12-10
RU2008117298A (ru) 2009-11-20
NO20082092L (no) 2008-07-04
ECSP088350A (es) 2008-05-30
EP1931676B1 (de) 2011-11-16
US20070083044A1 (en) 2007-04-12
BRPI0617150A2 (pt) 2011-07-12
AU2006299338A1 (en) 2007-04-12
WO2007041712A1 (en) 2007-04-12
AR056206A1 (es) 2007-09-26
JP5052518B2 (ja) 2012-10-17
JP2009511491A (ja) 2009-03-19
US7776865B2 (en) 2010-08-17
ZA200802995B (en) 2009-02-25
TW200745123A (en) 2007-12-16
IL190598A0 (en) 2008-11-03
KR20080063806A (ko) 2008-07-07
PE20070543A1 (es) 2007-06-14
CA2624882C (en) 2014-05-20
EP1931676A1 (de) 2008-06-18
JP2012082233A (ja) 2012-04-26

Similar Documents

Publication Publication Date Title
ATE533770T1 (de) Pyrazolopyrimidine als proteinkinaseinhibitoren
ATE501142T1 (de) Als proteinkinaseinhibitoren geeignete phenylacetamide
IL191294A0 (en) Imidazopyrazines as protein kinase inhibitors
DK1951724T3 (da) Sammensmeltede bicykliske mTOR-inhibitorer
DE60314427D1 (de) Pyrazolopyrimidine als hemmstoffe cyclin-abhängiger kinasen
ATE479434T1 (de) Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
DK1973910T3 (da) Pyrrolo[3,2-c]pyridin-4-on-2-indolinon-proteinkinaseinhibitorer
DE60317077D1 (de) Pyrazolopyrimidine als hemmstoffe cyclin-abhängiger kinasen
ATE530545T1 (de) Als kinaseinhibitoren geeignete pyrazolylaminopyridinderivate
ATE443706T1 (de) Pyrrolotriazinverbindungen als kinaseinhibitoren
DK1720882T3 (da) Pyrazolopyrimidin-derivater som cyclin-afhængige kinaseinhibitorer
ATE518860T1 (de) Pyrroloä2,3-büpyridinderivate als proteinkinaseinhibitoren
ATE523499T1 (de) Cyclopenta [d]-pyrimidine als akt-proteinkinasehemmer
DE602004025258D1 (de) Aminotriazol-verbindungen als proteinkinase-hemmer
ATE524467T1 (de) Neuartige aza-heterozyklen als kinase-inhibitoren
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
TWI372625B (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
DE602005020465D1 (de) Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
ATE492544T1 (de) Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
ATE531705T1 (de) Substituierte 2-chinolyloxazole geeignet als pde4 inhibitoren
DE602005022115D1 (de) Heteroaromatische chinolinverbindungen und deren verwendung als pde10-inhibitoren
ATE512972T1 (de) Pyrrolopyrazole als wirksame kinaseinhibitoren
HK1124039A1 (en) PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
ZA200709269B (en) Protein kinase inhibitors
ATE478868T1 (de) Pyrrolodihydroisochinoline als pde10- inhibitoren